Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration

Nihon University

Status and phase: Completed; Phase 4

Conditions: Age-related Macular Degeneration

Treatments: Drug: Aflibercept

Study type: Interventional

Funder types: Other

Identifiers

NCT01824225

NihonU-2

Details and patient eligibility

About

Evaluate a treatment result of every two months versus as needed (PRN) after 3 initial monthly intravitreal aflibercept for the Japanese age related macular degeneration.

Enrollment: 100 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of age-related macular degeneration

Exclusion criteria

• Any treatment before intravitreal Aflibercept for age-related macular degeneration.
• Visual acuity above 0.1 in decimal visual acuity

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

PRN injection of aflibercept

Active Comparator group

Description:

Intravitreal aflibercept

Treatment:

Drug: Aflibercept

Two months injection of aflibercept

Active Comparator group

Description:

Intravitreal afilibercept

Treatment:

Drug: Aflibercept